Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis' New Oncology CEO Liz Barrett Charts A Course, But It Will Require Jump-Starting New Brands

Executive Summary

Liz Barrett joined Novartis in February after leading Pfizer's oncology unit, taking over leadership of the business at a time of transition and tasked with building new blockbusters as old reliable work engines mature. She talked to Scrip about her plans for Novartis Oncology at ASCO.

You may also be interested in...



Cosentyx Carries Novartis Sales But Kymriah Manufacturing Gives Cause For Concern

The Swiss major is very happy indeed with the growth trajectory of Cosentyx and Entresto and pleased with how its migraine drug Aimovig has started. However the revelation of manufacturing problems with its CAR-T therapy Kymriah marred Novartis' second-quarter results.

AAA Ramps Up Lutathera Launch And Plans Expansion Under Novartis Ownership

Advanced Accelerator Applications is ramping up the launch of the first-in-class peptide receptor radionuclide therapy (PRRT), but Novartis has much broader ambitions for the radiopharmaceutical platform. AAA President Susanne Schaffert talked to Scrip about the growth strategy.

CDK4/6 Inhibitor Market Snapshot: New Drugs Jockey For A Piece Of The Multi-Billion Dollar Pie

Pfizer's Ibrance has a strong lead in the CDK4/6 space, but Novartis' Kisqali and Lilly's Verzenio are looking to carve out their own niches, expand the category and move into earlier treatment settings. Another scramble is on as well, to answer the question: what comes next?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132247

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel